Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Antibody recruits natural killer cells
What ifWhat if an antibody against the selected Vβ family recruited natural killer cells through its Fc region?
The antibody binds the selected Vβ family on the target cell surface and presents its Fc region to Fc receptors on natural killer cells. Clustering those receptors triggers release of cytotoxic granules toward the antibody-coated cell.
1.1Surface activation marker targeting
What ifWhat if the CAR recognized CD30 on malignant T cells that display this surface marker?
Claim language“beta-chain variable region (Vβ) subunit”
An extracellular binding domain recognizes CD30 on the target cell membrane. Binding activates the engineered effector cell and directs killing toward the CD30-expressing cell.
1.1Magnetic capture removes target cells
What ifWhat if antibody-coated magnetic particles removed T cells carrying the selected Vβ family from a collected cell suspension?
The particle-bound antibody binds cells that display the selected Vβ family. A magnetic field retains particles and attached cells while the remaining suspension passes through the separator.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Cell bank reference panel testing
A cell bank uses T cells bearing a Vβ-directed chimeric antigen receptor to check the identity of reference cell lines that display defined T-cell receptors. The panel contains a line displaying the target Vβ region, a line displaying a different Vβ region, and a line lacking surface T-cell receptor. Each reference line occupies a separate well with the same receptor-bearing sensor cells. A fluorescent activation reporter records the response for comparison with the expected pattern across the panel.
Component substitution
Single-domain binder for vβ recognition
A camelid single-domain antibody specific for the native Vβ region replaces the paired heavy- and light-chain variable domains of a single-chain antibody fragment. The single-domain binder sits at the extracellular end of the receptor and connects through a hinge to the transmembrane segment. The intracellular signaling domains remain on the cytoplasmic side of the membrane. Target-cell cocultures compare receptor activation across cells displaying the target Vβ region and cells displaying other Vβ regions.
Parameter or scale variation
Target density series for receptor testing
A supported lipid bilayer displays purified T-cell receptor ectodomains that contain the target Vβ region and attach through their membrane-proximal ends. Five surfaces present calibrated densities of 0, 10, 30, 100, and 300 ectodomains per square micrometre. Receptor-bearing reporter cells contact each surface, and fluorescence microscopy records intracellular calcium signals for 5 minutes. The fraction of responding cells and the time to first calcium rise describe how activation changes with target density.
Combination with existing systems
Single-cell pairing in a microfluidic array
A microfluidic imaging array places one Vβ-directed receptor-bearing cell and one target cell in each pairing trap. Fluorescent labels distinguish the two cell populations, and time-lapse microscopy records the start and duration of direct contact. A calcium indicator in the receptor-bearing cell reports signaling during each encounter. Parallel traps pair receptor-bearing cells with targets displaying a different Vβ region for comparison.
Spatial reporter assay in tissue sections
An organotypic culture system holds thin lymphoid tissue slices on porous membrane inserts. Fluorescently tracked T cells carrying a Vβ-directed receptor and an activation reporter are added to the exposed face of each slice. Live microscopy records cell positions and reporter activity through the slice. After imaging, staining for the target Vβ region maps the distribution of target cells against the recorded locations of reporter activation.
Automated or data-driven variant
Automated measurement of receptor selectivity
A liquid handler distributes Vβ-directed receptor-bearing reporter cells across a multiwell plate containing reference cells with identified Vβ regions. A flow cytometer measures reporter fluorescence, receptor surface expression, and reference-cell surface T-cell receptor abundance in each well. Analysis software applies gates defined by control wells and calculates the activated fraction within matched receptor-expression and target-abundance ranges. The output lists the response for each Vβ region and flags wells with too few viable cells for comparison.
Specific version of a part
Single domain antibody receptor
A single antibody variable domain recognizes an exposed epitope on the selected Vβ family. A hinge connects the binding domain to the transmembrane segment, and an intracellular signaling tail relays target engagement.
Receptor on natural killer cells
A natural killer cell displays a membrane-anchored receptor with an extracellular Vβ-binding domain and an intracellular activation domain. Binding to the selected Vβ family triggers the natural killer cell to release cytotoxic granules toward the bound cell.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1A chimeric antigen receptor (CAR) construct specific for a T-cell receptor (TCR) beta-chain variable region (Vβ) subunit of a T cell.
In one aspect, the invention provides a vector including (i) a first polynucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR includes an extracellular domain including a sequence that specifically binds to T Cell Receptor Beta Chain (TRBC)1 or TRBC2, and (ii) a second polynucleotide sequence encoding a guide RNA (gRNA), wherein the gRNA targets a T Cell Receptor (TCR) gene.
A · US 2021/0277120 A1 · ¶ 8
In some embodiments, the CAR T cells are engineered to express a chimeric antigen receptor that targets a tumor antigen.
B · US 2022/0016165 A1 · ¶ 32
An empty cell means only that no passage was reproduced there.
Statements in these documents
This would permit the generation, storage, and validation of “universal” T cells for use when needed.
A · US 2021/0277120 A1 · ¶ 5
There is a need for new approaches to overcome the challenges posed by existing methods for adoptive T cell therapy, in particular for T cell malignancies, such as those noted above.
A · US 2021/0277120 A1 · ¶ 7
There is a need to understand how attributes of CAR-positive T cells and patients' immunological status correlate with clinical outcomes.
B · US 2022/0016165 A1 · ¶ 4
In some aspects, the methods and uses provide for or achieve improved response and/or more durable responses or efficacy and/or a reduced risk of toxicity (e.g., CRS or ICANS) or other side effects, in subjects treated with some methods, as compared to certain alternative methods.
B · US 2022/0016165 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355238 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355238/, SHA-256 13606b29e946e3fe0f74c0278d4ba44e11a2130f5423fcc3ab595e5826171cb4